Drug toxicity: Idiosyncratic Reactions

Idiosyncratic reactions are unpredictable individual responses to chemicals that are unrelated to dose and vary widely among individuals. These reactions typically occur when drugs bind serum proteins to form haptens, triggering a toxic immune response. Interindividual differences are heavily influenced by pharmacogenetic factors, meaning genetic variations between people determine how they metabolize and respond to drugs.

Polymorphisms in CYP3A4 and CYP2D6, key hepatic enzymes, can markedly alter drug activity and half-life, increasing toxicity risk. Genetic variations in CYP2C9 affect warfarin's metabolism, while variations in VKORC1 influence clot formation. These enzyme differences mean individuals metabolize drugs at different rates, causing some to experience toxic effects at standard doses.

Approximately 10% of black males on primaquine treatment develop severe hemolytic anemia due to a genetic deficiency of erythrocyte glucose-6-phosphate dehydrogenase. This pharmacogenetic variation prevents normal red blood cell function when exposed to the drug, demonstrating how genetic polymorphisms create idiosyncratic reactions independent of drug dose.

The combined administration of a drug metabolized by cytochrome P450 with another drug that inhibits the enzyme heightens the risk of drug overdose toxicity. When an enzyme inhibitor is present, the first drug accumulates in the body because it cannot be metabolized efficiently, leading to elevated concentrations and potential toxicity even at normal doses.

When a drug binds covalently with serum proteins, it forms a foreign hapten that the immune system recognizes as a threat. This triggers an immunotoxicological response, causing the body to mount an abnormal reaction to the drug. Unlike allergic reactions, this response is not dose-dependent and varies significantly based on individual genetic and immune factors.

Polymorphisms in the NAT2 gene affect the metabolism of isoniazid, leading to different acetylation and clearance rates among individuals. Some people are fast acetylators who clear the drug quickly, while others are slow acetylators who accumulate it in their bodies. These genetic differences determine whether individuals experience therapeutic effects or toxic accumulation at standard doses.

Many drugs include warnings about potential drug-drug interactions in their prescribing information, underscoring the importance of considering genetic factors and possible interactions in drug therapy management. These warnings help clinicians identify patients at higher risk for idiosyncratic reactions based on their genetic profile and concurrent medications, enabling safer personalized treatment decisions.